The Delaware Supreme Court recently ruled on a significant case involving a merger dispute that could impact future corporate transactions. In the case CHP III, L.P. v. Benjamin F. Cravatt, the court upheld a lower court's decision to dismiss claims related to the merger of Vividion Therapeutics, Inc. This ruling affects shareholders and corporate governance, particularly in how intellectual property is valued during mergers.

The case centers around Vividion, which was founded in 2014 by Benjamin Cravatt and his colleagues at the Scripps Research Institute. In 2016, Vividion entered into a License Agreement with Scripps to fund Cravatt's research in exchange for rights to his discoveries. This included a key patent application, U.S. Patent Application 16/478,444, which became a focal point in the dispute.

In 2021, Bayer Corporation proposed to acquire Vividion for $2 billion. During the negotiations, Bayer conducted extensive due diligence on Vividion's intellectual property, including the License Agreement with Scripps. However, Vividion did not independently assess the value of its intellectual property or negotiate Bayer's offer, leading to a signed merger agreement at the proposed price.

To minimize the royalty payments Bayer would owe to Scripps, the merger agreement required Vividion to amend the License Agreement, specifically to relinquish rights to certain intellectual property. After the merger closed, Vividion released the license for the ‘444 Application, which was then licensed to Cravatt's new startup, Belharra Therapeutics, Inc. This led to allegations that Cravatt manipulated the merger process to conceal the value of the ‘444 Application, depriving Vividion's shareholders of potential additional merger consideration.

Cardinal, an investor in Vividion, filed a lawsuit in August 2024, claiming that Cravatt's actions constituted a breach of fiduciary duty, fraud, and unjust enrichment. The case was initially heard in the Delaware Court of Chancery, which dismissed Cardinal's claims as derivative, meaning they could not be pursued directly by Cardinal after the merger.

The Court of Chancery found that the essence of Cardinal's claims involved misrepresentations made after the merger agreement was signed, which could not affect the merger consideration. Cardinal appealed this decision, arguing that the trial court mischaracterized the nature of the claims and that they were direct claims under a different legal standard.

In its ruling, the Delaware Supreme Court reviewed the lower court's dismissal de novo, meaning it examined the case without deferring to the previous court's conclusions. The court noted that Cardinal's allegations suggested misconduct during the merger negotiations, including misrepresentations about the value of Vividion's intellectual property and the concealment of Belharra.

The court ultimately ruled that Cardinal failed to establish a direct claim under the legal standard set forth in Parnes v. Bally Entertainment. It emphasized that the merger agreement stipulated that the merger consideration would remain unchanged regardless of the intellectual property released. Therefore, Cardinal could not demonstrate that the alleged undervaluation of the ‘444 Application had a material impact on the merger price.

Additionally, the court found that Cardinal's claims of fraud did not meet the necessary legal standards. Cardinal did not provide sufficient details about the alleged misrepresentations or demonstrate that Bayer's due diligence was impeded in any way. As a result, the court affirmed the lower court's ruling, dismissing Cardinal's claims.

This ruling has significant implications for corporate governance and shareholder rights. It clarifies the standards for alleging direct claims in merger disputes and underscores the importance of thorough due diligence during corporate transactions. Shareholders may need to be more vigilant in assessing the actions of corporate directors and the valuation of intellectual property during mergers.

Looking ahead, the case sets a precedent for how similar disputes may be handled in the future. While the ruling cannot be appealed further, it highlights the complexities involved in corporate mergers and the legal challenges that can arise when shareholders believe their interests have been compromised.

Overall, the Delaware Supreme Court's decision in CHP III, L.P. v. Benjamin F. Cravatt reinforces the need for transparency and accountability in corporate governance, particularly in high-stakes merger negotiations.